The study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia

The research company Syndax Pharmaceuticals is conducting the clinical trial of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia.

The purpose of this study is to determine the safety and tolerability of SNDX-5613 when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory leukemias harboring lysine methyltransferase 2A (KMT2A) or mNPM1.

It is planned to include 54 participants.

Actual study start date is March 9, 2022. The researchers expect to complete the study by February 2024.

One primary outcome measure is Number of Participants With Dose Limiting Toxicities From SNDX-5613.

The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT05326516.